PCSK9 and atherosclerosis: The observed reduction in LDL-C levels of about 60% is comparable to what can be achieved by statins or PCSK9 antibodies [46], and the notion of sustained reductions in LDL-C might offer additional benefits as to the cumulative effects of LDL-C on atherosclerosis [47].